Criticism of the Food and Drug Administration
Numerous governmental and non-governmental organizations have criticized the U. S. Food and Drug Administration of either over- or under-regulation. The U.S. Food and Drug Administration (FDA) is an agency of the United States Department of Health and Human Services and is responsible for the safety regulation of most types of foods, dietary supplements, drugs, vaccines, biological medical products, blood products, medical devices, radiation-emitting devices, veterinary products, and cosmetics. The FDA also enforces section 361 of the Public Health Service Act and the associated regulations, including sanitation requirements on interstate travel as well as specific rules for control of disease on products ranging from animals sold as pets to donations of human blood and tissue.
A $1.8 million 2006 Institute of Medicine report on pharmaceutical regulation in the U.S. found major deficiencies in the FDA system for ensuring the safety of drugs on the American market. Overall, the authors called for an increase in the regulatory powers, funding, and independence of the FDA.
- 1 Charges of over-regulation
- 2 Charges of under-regulation
- 3 Charges of FDA bias
- 4 See also
- 5 References
- 6 External links
Charges of over-regulation
A group of critics claim that the FDA possesses excessive regulatory authority.
Alleged problems in the drug approval process
The economist Milton Friedman has claimed that the regulatory process is inherently biased against approval of some worthy drugs, because the adverse effects of wrongfully banning a useful drug are undetectable, while the consequences of mistakenly approving a harmful drug are highly publicised and that therefore the FDA will take the action that will result in the least public condemnation of the FDA regardless of the health consequences.
Friedman and others have argued that delays in the approval process have cost lives. The thalidimide birth defects crisis led to passage of the 1962 Kefauver Harris Amendment, which required proof of efficacy in addition to safety for approval of new drugs — despite the fact that the thalidimide crisis was entirely a safety issue. Proving efficacy is much more expensive and time-consuming than proving safety. By requiring proof of efficacy in addition to safety, the Kefauver Harris Amendment added considerable cost and delay to the drug approval process — which may well have cost many more lives than it was claimed to save. Prior to passage of the Kefauver Harris Amendment, the average time from the filing of an investigational new drug application (IND) to approval was 7 months. By 1998, it took an average of 7.3 years from the date of filing to approval. Prior to the 1990s, the mean time for new drug approvals was shorter in Europe than in the United States, although that difference has since disappeared.
Concerns about the length of the drug approval process were brought to the fore early in the AIDS epidemic. In the late 1980s, ACT-UP and other HIV activist organizations accused the FDA of unnecessarily delaying the approval of medications to fight HIV and opportunistic infections, and staged large protests, such as a confrontational October 11, 1988 action at the FDA campus which resulted in nearly 180 arrests. In August 1990, Louis Lasagna, then chairman of a presidential advisory panel on drug approval, estimated that thousands of lives were lost each year due to delays in approval and marketing of drugs for cancer and AIDS. Partly in response to these criticisms, the FDA introduced expedited approval of drugs for life-threatening diseases and expanded pre-approval access to drugs for patients with limited treatment options. All of the initial drugs approved for the treatment of HIV/AIDS were approved through accelerated approval mechanisms. For example, a "treatment IND" was issued for the first HIV drug, AZT, in 1985, and approval was granted 2 years later, in 1987. Three of the first 5 HIV medications were approved in the United States before they were approved in any other country.
Allegations that FDA regulation causes higher drug prices
Studies published in 2003 by Joseph DiMasi and colleagues estimated an average cost of approximately $800 million to bring a new drug to market, while a 2006 study estimated the cost to be anywhere from $500 million to $2 billion. The consumer advocacy group Public Citizen, using a different methodology, estimated the average cost for development to be under $200 million, about 29% of which is spent on FDA-required clinical trials. DiMasi rejects the claim that high R&D costs alone are responsible for high drug prices. Instead, in a published letter, DiMasi writes, "...longer development times increase R&D costs and shorten the period during which drug companies can earn the returns they need to make investment financially viable. Other things being equal, longer development times reduce innovation incentives. As a consequence, fewer new therapies might be developed."
Nobel prize-winning economist Gary S. Becker has argued that FDA-required clinical trials for new drugs do contribute to high drug prices for consumers, mainly because of patent protection that provides a temporary monopoly which disallows cheaper alternatives from entering into the market. He advocates dropping many FDA requirements, many of which provide no additional safety or valuable information, as this would hasten the development of new drugs, because they would be faster to bring to market, thereby increasing supply, and as a consequence would lead to lower prices. In 2011, the experience with Makena showed that a previously inexpensive drug could increase in price dramatically, from about $10 to $1,500 after the FDA regulated its marketing, approved it as orphan drug, and granted it a temporary monopoly status, although it had been on the market for five decades. After criticism, the FDA indicated that previous providers could continue to provide the medication, and Makena's price was reduced.
Allegations of censorship in food and drug labeling
The FDA has been criticized by advocates for the supplement industry for prohibiting dietary supplement manufacturers from making research supported claims of effectiveness on the labels of their products. Manufacturers of supplements, which are considered foods for regulatory purposes, are allowed to make only limited "structure/function claims" and are prohibited from claiming that the supplement can prevent, cure, or mitigate a disease or condition regardless of whether or not the supplement undergoes actual testing of its safety and efficacy. Ron Paul (R-TX) opined: "But the FDA and the drug companies are in bed together and they squeeze out competitions and build up their monopolies and they love government medicine because they make more money." Ron Paul also introduced a bill on November 10, 2005 titled the "Health Freedom Protection Act" (H.R. 4282), which proposed to stop "the FDA from censoring truthful claims about the curative, mitigative, or preventative effects of dietary supplements, and adopts the federal court’s suggested use of disclaimers as an alternative to censorship."
Charges of under-regulation
In contrast to those who see the FDA as a source of excessive regulation, other critics believe that the FDA does not regulate strictly enough. According to this view, the FDA allows unsafe drugs on the market because of pressure from pharmaceutical companies, fails to ensure safety in drug storage and labelling, and allows the use of dangerous agricultural chemicals, food additives, and food processing techniques.
A $1.8 million 2006 Institute of Medicine report on pharmaceutical regulation in the U.S. found major deficiencies in the current FDA system for ensuring the safety of drugs on the American market. Overall, the authors called for an increase in the regulatory powers, funding, and independence of the FDA.
Allegations that the FDA covered up exportation of unsafe products
In the 1980s, Cutter Laboratories introduced a heat-treated version of Factor VIII concentrate in the US, designed to eliminate the risk of HIV transmission. However, Cutter continued to market the untreated product overseas, potentially spreading HIV while the safer product was marketed in the US.
Cutter initially had a voluntary agreement with the FDA to stop marketing the untreated product. However, when it became clear that Cutter was not complying with the agreement, the FDA ordered the company to cease marketing untreated blood products, stating: "It was unacceptable for them to ship that material overseas." At the same time, the FDA, according to Cutter's internal documents, asked that the issue be "quietly solved without alerting the Congress, the medical community and the public", leading to charges that the FDA was complicit in covering up Cutter's actions.
Allegations that unsafe drugs are approved
Some critics believe that the FDA has been too willing to overlook safety concerns in approving new drugs, and is slow to withdraw approved drugs once evidence shows them to be unsafe. Rezulin (troglitazone) and Vioxx (rofecoxib) are high-profile examples of drugs approved by the FDA which were later withdrawn from the market for posing unacceptable risks to patients.
Troglitazone is a diabetes drug that was also available abroad at the time the FDA approved it. Post-marketing safety data indicated that the drug had dangerous side-effects (in this case liver failure). The drug was pulled off that market in the UK in 1997, but was not withdrawn by the FDA until 2000, before which time it is claimed that thousands of Americans were injured or killed by the drug.
In the case of Vioxx, a pre-approval study indicated that a group taking the drug had four times the risk of heart attacks when compared to another group of patients taking another anti-inflammatory, naproxen. The FDA approval board accepted the manufacturer's argument that this was due to a previously unknown cardioprotective effect of naproxen, rather than a risk of Vioxx, and the drug was approved. In 2005, the results of a randomized, placebo-controlled study showed that Vioxx users suffered a higher rate of heart attacks and other cardiovascular disorders than patients taking no medication at all. The manufacturer, Merck, withdrew the drug after disclosures that it had withheld information about its risks from doctors and patients for over five years, resulting in between 88,000 and 140,000 cases of serious heart disease of which roughly half died. David Graham, a scientist in the Office of Drug Safety within the CDER, testified to Congress that he was pressured by his supervisors not to warn the public about dangers of drugs like Vioxx. He argued that an inherent conflict of interest exists when the office responsible for post-approval monitoring of drug safety is controlled by the same organization which initially approved those same drugs as safe and effective. He said that after testifying against Vioxx, he was "marginalized by FDA management and not asked to participate in the evaluation of any new drug safety issues. It's a type of ostracism." In a 2006 survey sponsored by the Union of Concerned Scientists, almost one-fifth of FDA scientists said they "have been asked, for non-scientific reasons, to inappropriately exclude or alter technical information or their conclusions in a FDA scientific document."
Allegations that unsafe food additives and processing technologies are approved
Food safety advocates have criticized the FDA for allowing meat manufacturers to use carbon monoxide gas mixtures during the packaging process to prevent discoloration of meat, a process that may hide signs of spoilage from the consumer.
The FDA has been criticised for allowing the use of recombinant bovine growth hormone (rBGH) in dairy cows. rBGH-treated cows secrete higher levels of insulin-like growth factor 1 (IGF-1) in their milk than do untreated cows. IGF-1 signalling is thought to play a role in sustaining the growth of some tumors, although there is little or no evidence that exogenously absorbed IGF could promote tumor growth. The FDA approved rBGH for use in dairy cows in 1993, after concluding that humans drinking such milk were unlikely to absorb biologically significant quantities of bovine IGF-1. A 1999 report of the European Commission Scientific Committee on Veterinary Measures relating to Public Health noted that scientific questions persist regarding the theoretical health risks of milk from rBGH-treated cows, particularly for feeding to infants. Since 1993, all EU countries have maintained a ban on rBGH use in dairy cattle.
The FDA has also been criticised for permitting the routine use of antibiotics in healthy domestic animals to promote their growth, a practice which allegedly contributes to the evolution of antibiotic-resistant strains of bacteria. The FDA has taken recent steps to limit the use of antibiotics in farm animals. In September 2005, the FDA withdrew approval for the use of the fluoroquinolone antibiotic enrofloxacin (trade name Baytril) in poultry, out of concern that this practice could promote bacterial resistance to important human antibiotics such as ciprofloxacin.
The FDA has received criticism for its approval of certain coal tar derived food dyes such as FDC yellow 5 and 6, which are banned in most European countries. On September 6, 2007, the British Food Standards Agency revised advice on certain artificial food additives, including tartrazine.
Professor Jim Stevenson from Southampton University, and author of the report, said: "This has been a major study investigating an important area of research. The results suggest that consumption of certain mixtures of artificial food colours and sodium benzoate preservative are associated with increases in hyperactive behaviour in children.
The following additives were tested in the research:
- Sunset yellow (FD&C Yellow #6) – Coloring found in squashes
- Carmoisine – Red coloring in jellies
- Tartrazine (FD&C Yellow #5) – Yellow coloring
- Ponceau 4R – Red coloring
- Sodium benzoate – Preservative
- Quinoline yellow – Food coloring
- Allura red AC (FD&C Red #40) – Orange / red food dye
On April 10, 2008, the Food Standards Agency called for a voluntary removal of the colors (but not sodium benzoate) by 2009. In addition, it recommended that there should be action to phase them out in food and drink in the European Union (EU) over a specified period.
UK ministers have agreed that the six colorings will be phased out by 2009. A Japanese group found in 1987 that tartrazine was not carcinogenic after being fed to mice for two years. A German group found in 1989 that Sunset Yellow did not induce mutations that could lead to cancer in laboratory animals.
The FDA has also been criticized for giving permission for cloned animals to be sold as food without any special labelling, although "cloned products may not reach the U.S. market for years." "Authorities lack the authority to require labeling of products from cloned animals."
Charges of FDA bias
Allegations of undue pharmaceutical industry influence
After his resignation from his post as Commissioner of the FDA in December 1969, Herbert L. Ley, Jr., in an interview with the New York Times, warned the public about the FDA’s inability to safeguard consumers. People were being misled, he believed: “The thing that bugs me is that the people think the FDA is protecting them – it isn’t. What the FDA is doing and what the public thinks it’s doing are as different as night and day,” he said. The agency, in his opinion, did not have the motivation to protect consumers, faced budget shortfalls, and lacked support from the Department of Health,Education, and Welfare. Ley was critical of Congress, the Administration and the drug industry; he stated that he had "constant, tremendous, sometimes unmerciful pressure" from the drug industry and that the drug company lobbyists, combined with the politicians who worked on behalf of their patrons, could bring “tremendous pressure” to bear on him and his staff, to try preventing FDA restrictions on their drugs. The interview concluded with Ley stating that the entire issue was about money, “pure and simple”.
In an interview for the oral history program of the FDA History Office, Ley shared that from the first controversy in his tenure as FDA Commissioner he had a "gut feeling" that his life expectancy at the FDA was probably limited. The controversy involved the drug company Upjohn and their patented drug Panalba. Panalba was a combination of tetracycline, an inexpensive and effective generic drug, with an added, more toxic, compound. Although Upjohn had been marketing the drug for 7 years, they had not done any of the required efficacy studies. However, the FDA had done one study that showed Panalba to be no more effective than tetracycline, and they moved to decertify it. Ley said he had done everything by the book and had drawn on all of the people that were involved, both in the FDA and the Department of Health,Education, and Welfare, but he met tremendous opposition from Upjohn, and he felt that the Administration was wishing that he would stonewall the whole report because it was goring too many pharmaceutical companies.
In a 2005 interview, Dr. David J. Graham, associate director of the FDA's Office of Drug Safety, was asked "What Specifically do you believe is broken in the FDA and what needs to be done to fix it? What must be done to improve the drug vetting system ?" his response: " FDA is inherently biased in favor of the pharmaceutical industry. It views industry as its client, whose interests it must represent and advance. It views its primary mission as approving as many drugs it can, regardless of whether the drugs are safe or needed"
Critics have disputed the claim that the Prescription Drug User Fee Amendment has improved the speed of drug approvals. Former Editor of The New England Journal of Medicine, Marcia Angell, has stated that "It's time to take the Food and Drug Administration back from the drug companies.... In effect, the user fee act put the FDA on the payroll of the industry it regulates. Last year, the fees came to about $300 million, which the companies recoup many times over by getting their drugs to market faster."
Allegations of bias against gay men in blood donation process
Blood collecting organizations, such as the American Red Cross, have policies in accordance with FDA guidelines that prohibit accepting blood donations from any "male who has had sex with another male since 1977, even once". The inclusion of homo- and bisexual men on the prohibited list has created some controversy, but the FDA and Red Cross cite the need to protect blood recipients from HIV as justification for the continued ban. Even with PCR-based testing of blood products, a "window period" may still exist in which an HIV-positive unit of blood would test negative. All potential donors from HIV high-risk groups are deferred for this reason, including men who have sex with men. The issue has been periodically revisited by the Blood Products Advisory Committee within the FDA Center for Biologics Evaluation and Research, and was last reconfirmed on May 24, 2007. Documentation from these meetings is available.
However, in 2006, the AABB, America's Blood Centers and American Red Cross recommended to the FDA that the deferral period for men who had sex with other men should be changed to be equivalent with the deferral period for heterosexual's judged to be at risk. The FDA chose to uphold the blood ban. Female sexual partners of MSM (men who have sex with men) are deferred for one year since the last exposure. This is the same policy used for any sexual partner of someone in a high-risk group. The intent of these policies is to ensure that blood is collected from a population that is at low risk for disease, since the tests are not perfect and human error may lead to infected units not being properly discarded. The policy was first put in place in 1985.
Criticism of FDA's rejection of medical cannabis
In April 2005, the FDA issued a statement asserting that cannabis had no medical value and should not be accepted as a medicine, despite a great deal of research suggesting the opposite. The supporters of medical cannabis legalization criticized the FDA's statement as a politically motivated one instead of one based on solid science. A group of congressmen led by Maurice Hinchey wrote a letter to FDA's commissioner Andrew von Eschenbach, expressing their disapproval of the FDA's statement and pointed out the FDA's rejection of medical cannabis was inconsistent with the findings of the Institute of Medicine, which stated cannabis does have medical benefits. While the FDA has not approved marijuana it has approved THC (a compound found in cannabis) as an active ingredient for medicinal use. Critics argue that this approval is a politically motivated attempt to allow special interest groups to have patents over the substance, perhaps because the patents on previously patented competing substances have expired.
Allegations regarding management and FDA scientists
|Wikinews has related news: Obama calls food safety system a 'hazard to public health'|
Nine FDA scientists appealed to President George W. Bush and at the time, President-elect Barack Obama over pressure from management to manipulate data, mainly in relation to the review process for medical devices. These concerns were highlighted in a 2006 report on the agency as well.
- History of the FDA, FDA.gov
- Henderson, Diedtra (September 23, 2006). "Panel: FDA needs more power, funds". Boston Globe. 
- Committee on the Assessment of the US Drug Safety System. (2006). The Future of Drug Safety: Promoting and Protecting the Health of the Public. Institute of Medicine. Free full-text.
- Carpenter DP (2004). "The political economy of FDA drug review: processing, politics, and lessons for policy". Health Affairs 23 (1): 53–63. doi:10.1377/hlthaff.23.1.52. PMID 15002628.
- "Chapter 7 -- Who Protects the Consumer?". Free to Choose (First Harvest Edition 1990 ed.). Harvest House. 1980. pp. 203–210. ISBN 978-0-15-633460-0.
- TAKE IT TO THE LIMITS: Milton Friedman on Libertarianism. Transcript from television show filmed February 10, 1999. Retrieved from Hoover Institution website.
- History of Federal Regulation: 1902–Present (2008). "Kefauver-Harris Amendments of 1962". FDAReview.org. The Independent Institute. Retrieved 2013-12-02.
- Gaby, Alan R (August 1, 2010). "Should the Kefauver-Harris Amendment be repealed?". biomedsearch.com. Townsend Letter. Retrieved 2013-12-02.
- Gieringer DH (1985). "The safety and efficacy of new drug approval". Cato Journal 5 (1): 177–201. PMID 11616801.
- FDAreview.org. Theory, Evidence and Examples of FDA Harm, citing Peltzman, S. 1973. An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments. Journal of Political Economy 81, no. 5: 1049–91. Reprinted in Chicago Studies in Political Economy, edited by George J. Stigler, 303–48. Chicago, University of Chicago Press, 1988. and Thomas, L. G. 1990. Regulation and Firm Size: FDA Impacts on Innovation. Rand Journal of Economics 21, no. 4: 497–517.
- http://www.diahome.org/content/abstract/1999/d334969.pdf Healy, Elaine, and Kenneth Kaitin. 1999. The European Agency for the Evaluation of Medicinal Product’s Centralized Procedure for Product Approval: Current Status. Drug Information Journal 33: 969–78.
- ACT-UP NY timeline.
- Faster Approval of AIDS Drugs Is Urged. The New York Times, August 16, 1990, Thursday, Late Edition – Final, Section B; Page 12, Column 4; National Desk, 830 words, By ROBERT PEAR, Special to The New York Times, WASHINGTON, Aug. 15
- FDA Website: Expanded Access and Expedited Approval of New Therapies Related to HIV/AIDS.
- http://www.fda.gov/fdac/special/newdrug/speeding.html FDA report on accelerated approval process
- FDA press release on 3TC approval.
- DiMasi J (2002). "The value of improving the productivity of the drug development process: faster times and better decisions". PharmacoEconomics. 20 Suppl 3: 1–10. doi:10.2165/00019053-200220003-00001. PMID 12457421.
- DiMasi J, Hansen R, Grabowski H (2003). "The price of innovation: new estimates of drug development costs". J Health Econ 22 (2): 151–85. doi:10.1016/S0167-6296(02)00126-1. PMID 12606142..
- Adams C, Brantner V (2006). "Estimating the cost of new drug development: is it really 802 million dollars?". Health Aff (Millwood) 25 (2): 420–8. doi:10.1377/hlthaff.25.2.420. PMID 16522582.
- 2001 Public Citizen Report on Drug Development Costs.
- Public Citizen response to 2003 DiMasi papers.
- DiMasi JA (Jul–August 2006). "What's time got to do with it?". Health Aff (Millwood) 25 (4): 1188. doi:10.1377/hlthaff.25.4.1188. PMID 16835212.
- Becker, Gary. Power to the Patients. AEI-Brookings Joint Center Policy Matters 04-15. Originally published in The Milken Institute Review, 2nd quarter 2004.
- Becker, Gary S. Get the FDA Out of the Way, and Drug Prices Will Drop, Business Week Magazine, September 16, 2002.
- Daily Mail (March 9, 2011). "Preemie outrage: Cost of drug that prevents premature birth to rise from $10 to $1500.". Retrieved March 10, 2011.
- "Ron Paul: FDA And Big Pharma 'Are In Bed Together'". Dailypaul.com. April 10, 2012. Retrieved 18 October 2013.
-  "Free Speech and Dietary Supplements" by Representative Ron Paul, Before the US House of Representatives, November 10, 2005
-  Health Freedom Protection Act
- http://www.lewrockwell.com/paul/paul288.html "Free Speech and Dietary Supplements"
- Henderson, Diedtra (September 23, 2006). "Panel: FDA needs more power, funds". Boston Globe. 
-  Executive Summary of the 2006 IOM Report The Future of Drug Safety: Promoting and Protecting the Health of the Public
- Bogdanovich, Walt; Eric Koli (May 22, 2003). "2 Paths of Bayer Drug in 80's: Riskier One Steered Overseas". New York Times. Retrieved January 27, 2009.
-  David Graham's 2004 testimony to Congress
- Bombardier C, Laine L, Reicin A, et al. (November 2000). "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group". N. Engl. J. Med. 343 (21): 1520–8, 2 p following 1528. doi:10.1056/NEJM200011233432103. PMID 11087881.
- Bresalier RS, Sandler RS, Quan H, et al. (March 2005). "Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial". N. Engl. J. Med. 352 (11): 1092–102. doi:10.1056/NEJMoa050493. PMID 15713943.
- "The Cover-Up Artist". Slate. 2011-11-14. p. 1.
-  2006 Union of Concerned Scientists survey of FDA Scientists
- "Some raising red flag over use of gas to keep meat in the pink". Pittsburgh Post-Gazette. February 19, 2006.
- Juskevich JC, Guyer CG (August 1990). "Bovine growth hormone: human food safety evaluation". Science 249 (4971): 875–84. doi:10.1126/science.2203142. PMID 2203142.
- http://ec.europa.eu/food/fs/sc/scv/out19_en.html 1999 report of the European Commission Scientific Committee on Veterinary Measures relating to Public Health
- Myllys V, Honkanen-Buzalski T, Huovinen P, Sandholm M, Nurmi E (1994). "Association af changes in the bacterial ecology of bovine mastitis with changes in the use of milking machines and antibacterial drugs". Acta Vet Scand 35 (4): 363–9. PMID 7676918.
- http://www.fda.gov/cvm/FQWithdrawal.html FDA statement on withdrawal of Baytril for use in poultry
- "Parents warned of additives link". BBC News. 2007-09-06. Retrieved 2009-04-15.
- BBC Europe-wide food colour ban call April 10, 2008
- FSA Board discusses colours advice April 10, 2008
- BBC Ministers agree food colour ban November 12, 2008
- Maekawa A, Matsuoka C, Onodera H, Tanigawa H, Furuta K, Kanno J, Jang J, Hayashi Y, Ogiu T (1987). "Lack of carcinogenicity of tartrazine (FD & C Yellow No. 5) in the F344 rat". Food Chem Toxicol 25 (12): 891–6. doi:10.1016/0278-6915(87)90281-X. PMID 3692395.
- Wever J, Münzner R, Renner H (1989). "Testing of sunset yellow and orange II for genotoxicity in different laboratory animal species". Environ Mol Mutagen 13 (3): 271–6. doi:10.1002/em.2850130311. PMID 2651119.
- Catherine Larkin, "Cloned Animals Are Safe for U.S. Food, Agency Says (Update7)", found at Bloomberg.com website. Accessed January 15, 2008.
- Data gaps in toxicity testing of chemicals allowed in food in the United States
- Jennifer ross-nazzal. "From Farm to Fork": How Space Food Standards Impacted the Food Industry and Changed Food Safety Standards page 226. NASA History Division. Retrieved August 25, 2013.
- Richard D. Lyons (December 31, 1969). Ousted F.D.A. Chief Charges 'Pressure' From Drug Industry . New York Times. Retrieved August 25, 2013.
- Oral Histories . FDA. Retrieved August 25, 2013.
- The FDA's History Office (December 15, 1999). Oral history of the U.S Food and Drug Administration – Herbert L. Ley M.D. Page 19 . FDA. Retrieved August 25, 2013.
- DICK CAROZZA (September/October 2005) FDA Incapable of Protecting U.S., Scientist Alleges . Fraud Magazine Cover Story. Retrieved August 26, 2013.
- DICK CAROZZA (September/October 2005) FDA Incapable of Protecting U.S., Scientist Alleges . National Health Federation (Full original interview available with the permission of Fraud Magazine). Retrieved August 26, 2013.
- Carpenter D. et al. (2003). "Approval times for new drugs: does the source of funding for FDA staff matter?". Health Affairs (Millwood). Suppl Web Exclusives:W3: 618–24. PMID 15506165.
- Marcia Angell (February 26, 2007) Taking back the FDA. Boston.com. Retrieved August 26, 2013.
- http://www.harbus.org/2002/American-Red-Cross-Dogged-1043/ 2002 article in The Harbus regarding the blood donor guideline controversy
- http://www.fda.gov/cber/faq/bldfaq.htm CBER blood products FAQ
- http://www.fda.gov/ohrms/dockets/ac/acmenu.htm FDA advisory committee documents
- AABB Homepage
- 1992 Recommendations for the prevention of Human Immunodeficiency Virus Transmission by Blood and Blood Products
- "American Red Cross Dogged by Allegations of Discrimination (published: January 28, 2002)". The Harvard business school newspaper. Retrieved 2006-12-17.
- FDA on Medical Marijuana: Science or Politics? Joanne Silberner
- Hinchey Leads Bipartisan House Coalition In Calling For FDA Americans for Safe Access
- "Medical" Marijuana – The Facts
- Researchers scramble for THC patent
- Mundy A, Favole JA. (2008). FDA Scientists Ask Obama to Restructure Drug Agency. WSJ.
- PDF – June 2007 report from the Competitive Enterprise Institute
- PDF – February 2010 issue of Mercatus On Policy
- Henninger, Daniel (2002). "Drug Lag". In David R. Henderson (ed.). Concise Encyclopedia of Economics (1st ed.). Library of Economics and Liberty. OCLC 317650570, 50016270 and 163149563